• Skip to main content
  • Skip to footer

Delphi Diagnostics

Delphi Diagnostics guides personalized breast cancer therapy decisions with the Endocrine Activity Index

  • Technology
    • Lead Inventor
    • Endocrine Activity Index
    • Intellectual Property
  • Our Mission
  • Our Company
    • Board of Directors
    • Executive Team
    • Advisory Board
    • Trusted Collaborators
  • News
  • Contact Us

Cancer Research

SET2,3TM index adds independent, complementary information to personalize breast cancer treatment

December 14, 2021 by Emily Granger

December 14, 2021 Delphi Diagnostics Inc. is pleased to announce that its SET2,3 index, a standard measure of gene expression known as the Sensitivity-to-Endocrine-Therapy, was found to have prognostic value that complements the known prognostic value of the 21-gene Oncotype DX Recurrence Score in an analysis of data from postmenopausal patients with hormone receptor-positive breast […]

Filed Under: Cancer Research

Footer

Join us on:

  • LinkedIn
  • Privacy Policy
  • Contact Us
  • News

Copyright © 2025 · Delphi Diagnostics, Inc.™ All rights reserved.